Toward the harmonization of immune monitoring in clinical trials: quo vadis?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.PloS one · 2011
   Pooled it
2. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2011
   Trial
3. Beyond tumor biology: nursing interventions for psychological and immune health in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
   Review
4. Immunomonitoring in bladder cancer: a short report on stability of leukocytes and proteins in refrigerated urine samples.BMC urology · 2024
   Article
5. Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.Frontiers in immunology · 2022
   Article
6. Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.Vaccines · 2018
   Article
7. Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.Journal of translational medicine · 2014
   Review
8. Managing Multi-center Flow Cytometry Data for Immune Monitoring.Cancer informatics · 2014
   Article
9. Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.BMC bioinformatics · 2013
   Article
10. Ancillary study management systems: a review of needs.BMC medical informatics and decision making · 2013
    Article
11. Structured reporting of T cell assay results.Cancer immunity · 2013
    Article
12. Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring.Oncoimmunology · 2012
    Article
13. The immuno-oncology framework: Enabling a new era of cancer therapy.Oncoimmunology · 2012
    Article
14. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.Nature reviews. Cancer · 2011
    Review
15. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Vaccine · 2011
    Review
16. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.Journal of translational medicine · 2011
    Article
17. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
    Review
18. Response definition criteria for ELISPOT assays revisited.Cancer immunology, immunotherapy : CII · 2010
    Article
19. Improved endpoints for cancer immunotherapy trials.Journal of the National Cancer Institute · 2010
    Review
20. New approaches to design HIV-1 T-cell vaccines.Current opinion in HIV and AIDS · 2010
    Review

Corrections and comments

• Comment on
  Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).2008
• Comment on
  The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.2008

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as